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 Statements 
 
• Whats already known about this topic: (word limit: 70 words; word count: 70 words) 
o Patients with atopic dermatitis (AD) inadequately controlled with topical therapy 
have few systemic treatment options 
o Ciclosporin A (CsA) is a systemic immunosuppressant approved for AD in most 
European countries and Japan, but not all patients respond, and side effects limit its 
use  
o Dupilumab (monoclonal antibody against interleukin-4 receptor-alpha) with/without 
topical corticosteroids (TCS) is approved in the U.S.A. and E.U. for the treatment of 
adults with moderate-to-severe AD 
• What does this study add: (word limit: 70 words; word count: 56 words) 
o In this 16-week trial in adults with AD and history of inadequate response 
to/intolerance of/medically inadvisable for CsA, dupilumab administered weekly or 
every 2 weeks with concomitant TCS significantly improved signs and symptoms and 
quality of life, with no new safety signals  
o These data support the use of dupilumab in this difficult-to-treat population 
 
SUMMARY  
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that may require systemic 
therapy. Ciclosporin A (CsA) is a widely-used, potent immunosuppressant for AD. CsA is not effective 
in all patients, and side effects limit its use. Dupilumab, a fully human anti-interleukin (IL)-4 receptor-
alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2/Th2-mediated 
inflammation, and is approved in the U.S.A. and the E.U. for the treatment of adults with moderate-
to-severe AD. 
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Objectives: To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids 
(TCS) in adults with AD with inadequate response to/intolerance of CsA, or for whom CsA was 
medically inadvisable. 
Methods: In this 16-week, double-blind, randomized, placebo-controlled, phase 3 trial, patients 
were randomized 1:1:1 to subcutaneous dupilumab 300 mg weekly (qw):every two weeks 
(q2w):placebo. All received concomitant medium-potency TCS from Week о2 through Week 16; 
dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS. 
Results: 390 patients were screened; 325 were randomized and 318 completed the trial. Treatment 
groups had similar baseline characteristics. Significantly more patients on dupilumab 
qw+TCS/q2w+TCS achieved ш75% improvement from baseline in Eczema Area and Severity Index at 
Week 16 vs placebo+TCS (primary endpoint) (59.1%/62.6% vs 29.6%; P<0.0001 vs placebo+TCS, both 
doses). Dupilumab qw+TCS/q2w+TCS significantly improved other clinical outcomes and AD 
symptoms, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and 
quality of life (QOL). Treatment groups had similar overall rates of adverse events 
(69.1%/72.0%/69.4%; qw+TCS/q2w+TCS/placebo+TCS) and serious adverse events 
(1.8%/1.9%/1.9%). Conjunctivitis was more frequent with dupilumab+TCS; skin infections were more 
frequent with placebo+TCS. 
Conclusions: Dupilumab+TCS significantly improved signs and symptoms of AD and QOL in adults 
with history of inadequate response to/intolerance of CsA, or for whom CsA treatment was 
medically inadvisable. No new safety signals were identified. (ClinicalTrials.gov Identifier: 
NCT02755649; EudraCT: 2015-002653-35) 
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INTRODUCTION 
Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease that features activation of type 
2/T-helper (Th2) immune responses, and altered skin barrier and skin microbiome.17 For patients 
with inadequate response or intolerance to topical therapies, guidelines recommend systemic 
immunosuppressants (e.g. ciclosporin A [CsA], methotrexate, azathioprine, or mycophenolic acid), 
although these treatments show variable efficacy/effectiveness and tolerability, and may be 
complicated by adverse effects and adverse medication interactions both in the short and long 
term.817 Phototherapy is also recommended, but cannot be used as long-term treatment and has 
risks including burning, skin aging, adverse medication interactions, and skin cancer.817  
Unlike other systemic immunosuppressants, CsA is approved in many European countries and Japan 
for severe AD when systemic therapy is required. CsA suppresses Th1, Th2, and Th17/22, affecting 
both humoral and cellular immune responses.18,19 Long-term use (beyond 1 year) of CsA, as may be 
required in AD, is limited by risk of side effects, although off-label use beyond 1 year has been 
reported.16,2038 Side effects associated with CsA include hypertension, nephrotoxicity, and subjective 
side effects (e.g. headache, paresthesia in fingers and toes, fatigue).16,2038 Its use is also limited by 
contraindications due to other medical conditions. Thus, patients with AD who are unresponsive to 
or who are unable to use topical medications or CsA have few treatment options. Given the 
chronicity of AD and the need for long-term pharmacologic therapy, new treatment options with 
better benefit-risk profiles are needed.  
Dupilumab, a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor-
alpha, is a targeted agent that selectively inhibits signalling of IL-4 and IL-13, key cytokines of type 
2/Th2 inflammation.39 Dupilumab is approved in the U.S.A. for the treatment of adults with 
moderate-to-severe AD whose disease is inadequately controlled by topical therapies, or when such 
treatments are not advisable, and can be used with or without topical corticosteroids (TCS).40 
Dupilumab has also been approved by the European Medicines Agency for use in adults with 
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moderate-to-severe AD who are candidates for systemic therapy.41 In patients with moderate-to-
severe AD who had inadequate response to topical medications, dupilumab alone or with TCS 
significantly improved clinical signs and symptoms of AD.4247 In these studies, adverse events (AEs) 
that were more frequent with dupilumab included conjunctivitis and injection-site reactions, but 
there was no increase in infections or serious AEs (SAEs) compared with placebo.4246 In addition, 
dupilumab is being investigated in other type 2/Th2 diseases. Positive data have been reported in 
clinical trials with dupilumab in patients with asthma,4850 chronic rhinosinusitis with nasal polyposis 
(CRsNP),51 and eosinophilic esophagitis,52 providing evidence of a common type 2/Th2 mechanism 
underlying these diseases.  
The present study expands upon previous studies of dupilumab in patients with moderate-to-severe 
AD by evaluating the efficacy and safety of dupilumab with concomitant TCS in patients with AD and 
a history of inadequate response or intolerance to CsA, or CSA-naive patients for whom CsA 
treatment was medically inadvisable. 
 
METHODS 
Study design 
LIBERTY AD CAFÉ (ClinicalTrials.gov Identifier: NCT02755649; EudraCT: 2015-002653-35) was a 
randomised, double-blind, placebo-controlled, parallel-group, phase 3 clinical study (Fig. 1). Patients 
were enrolled at academic institutions, hospitals, and clinics in 10 European countries in which 
systemic CsA has been approved for AD (Table S1). Patients were recruited by individual sites, based 
on reviews of patient databases, referrals, and advertising. 
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Patients 
Main inclusion criteria were: ш18 years of age with chronic AD according to American Academy of 
Dermatology consensus criteria;1 treatment with potent TCS indicated; inadequate response to TCS 
(as defined by investigator) within 6 months before screening; history of (1) prior CsA exposure and 
either inadequate response to CsA, requirement for CsA at doses or durations beyond those 
specified in prescribing information, or intolerance and/or unacceptable toxicity, or (2) CsA-naive 
and not eligible for CsA due to medical contraindications (e.g. uncontrolled hypertension on 
medication), use of prohibited concomitant medications, increased susceptibility to CsA-induced 
renal damage (elevated creatinine) and/or liver damage (elevated liver function tests), increased risk 
of serious infection, or hypersensitivity to CsA active substance or excipients; Eczema Area Severity 
Index (EASI) score ш20 at screening and baseline; Investigators Global Assessment (IGA) score ш3 
(scale 0 [clear] to 4 [severe]) at screening and baseline; ш10% body surface area (BSA) of AD 
involvement at screening and baseline. See Supporting Information for full inclusion/exclusion 
criteria. 
 
Ethics 
This study was conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, and are consistent with International Council for Harmonisation guidelines 
for Good Clinical Practice and applicable regulatory requirements. All patients provided signed 
written informed consent prior to any study procedure. Prior to study initiation, Institutional Review 
Boards (Table S1) and Independent Ethics Committees reviewed and approved the protocol, 
informed consent form, and patient information. An independent data monitoring committee 
(IDMC) monitored patient safety. 
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Study procedures, randomization, and treatments 
The screening period ran from Day о28 to baseline, and included a TCS standardization period, which 
ran from Day о14 to baseline (Fig. 1). At baseline, patients were randomized (1:1:1) to receive 16 
weeks of subcutaneous dupilumab 300 mg weekly (qw):every 2 weeks (q2w):placebo, using a central 
interactive voice/web response randomization system, stratified by baseline IGA score (3 or 4) and 
prior CsA exposure (yes/no). At baseline, patients received a loading dose of 600 mg dupilumab or 
matching placebo, followed thereafter by subcutaneous dupilumab 300 mg qw or q2w, or placebo. 
For blinding purposes, patients assigned to dupilumab q2w+TCS received placebo on weeks when 
dupilumab was not administered. Blinded study drug (dupilumab or placebo) was provided in coded 
kits with a medication numbering system. Except for the statistician who provided the 
randomization sequence, the IDMC statistician, and IDMC members, the study remained blinded to 
all individuals until prespecified unblinding. Emergency unblinding was permitted for a medical 
emergency, a SAE that was unexpected or for which a causal relationship to study drug could not be 
ruled out, or for any other significant medical event. During Weeks 1728, patients were followed 
for safety or could enter an open-label extension study (R668-AD-1225; ClinicalTrials.gov: 
NCT01949311; EudraCT: 2013-001449-15).  
During the initial two weeks of the screening period, patients could use TCS at investigator 
discretion. Starting at Day о14, and during the study treatment period, all eligible patients applied 
medium-potency TCS once daily to active lesion areas, or low-potency TCS on areas of thin skin (e.g. 
face, neck, intertriginous and genital areas) or where continued treatment with medium-potency 
TCS was considered unsafe. Patients could stop TCS upon adverse reaction to TCS. Patients achieving 
IGA=0 by Weeks 4, 8, or 12 could taper TCS to every other day. After Week 4, patients remaining at 
IGA=0 for 4 weeks could switch TCS to twice per week; if they did not remain at IGA=0 they would 
revert to daily dosing. Patients with clear skin continued to apply TCS to lesion-prone areas at 
intervals of every other day (if prior to Day 57) or twice weekly (after Day 57), as described above. 
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During the safety follow-up, patients could remain on TCS at investigator discretion. Patients 
recorded TCS use in a medication diary; tubes were weighed at each visit through Week 16. Patients 
were instructed to apply emollients twice daily for the 7 days prior to randomization and throughout 
the study; stable doses of prescription moisturizers or moisturizers containing additives were 
permitted if initiated before screening. 
Patients could receive rescue medication, including potent or very potent TCS, topical calcineurin 
inhibitors, or systemic medication, if medically necessary (e.g. to control intractable AD symptoms), 
at investigator discretion. Patients who received rescue medication were considered treatment 
failures, but continued study visits and assessments; those on topical rescue medication could 
continue study treatment, while those on systemic rescue medication discontinued study treatment 
(see Supporting Information: prohibited concomitant medications).  
 
Endpoints 
The primary endpoint was the proportion of patients with ш75% improvement from baseline in EASI 
score (EASI-75) at Week 16. Secondary endpoints were the following (all at Week 16, unless 
otherwise indicated): percent change from baseline in EASI, SCORing AD (SCORAD), weekly average 
of peak daily pruritus numerical rating scale (NRS) (Weeks 2 and 16), and Global Individual Sign Score 
(GISS); change from baseline in percent BSA affected by AD, Dermatology Life Quality Index (DLQI), 
Patient Oriented Eczema Measure (POEM), and Hospital Anxiety and Depression Scale (HADS); mean 
weekly dose of TCS during the treatment period; proportions of patients with ш50% or ш90% 
improvement from baseline in EASI score (EASI-50 or EASI-90), EASI-75 (among patients with prior 
CsA exposure), ш4-point reduction in weekly average of peak daily pruritus NRS score (among 
patients with baseline pruritus NRS score ш4), ш50% improvement from baseline in SCORAD 
(SCORAD-50), and both IGA 0 or 1 (clear or almost clear) and 2-point reduction in IGA from baseline. 
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Post hoc analyses included: mean change from baseline in EASI, SCORAD, and pruritus NRS scores; 
mean change from baseline in SCORAD visual analogue scale for sleep; and proportions of patients 
reporting no problem on the pain/discomfort subscale on the generic 5-dimension 3-level EuroQoL 
scale (among patients reporting moderate-to-severe pain/discomfort at baseline), reporting no 
days or 12 days for number of nights sleep was disturbed in the past week (POEM item 2) 
(among patients reporting 37 nights missed sleep the previous week at baseline), achieving ш4-
point improvement in DLQI score (minimal clinically important difference [MCID]) (among patients 
with baseline DLQI ш4),53 achieving ш4-point improvement in POEM score (MCID) (among patients 
with baseline POEM ш4),54 and achieving HADS anxiety (HADS-A) and depression (HADS-D) scores <8 
(among patients with HADS-A or HADS-D ш8 at baseline).55 
 
Statistical analyses 
Approximately 110 patients were planned for each treatment group  approximately 70 with 
previous exposure to CsA and 40 with no exposure (see Supporting Information). Target accrual was 
approximately 330 patients (110 per arm, including 70 with prior CsA exposure and 40 with no prior 
CsA exposure); this provided 99% power for the primary endpoint, assuming EASI-75 rates of 60.1% 
in the dupilumab arms and 26.4% in the placebo group, based on results of a 16-week phase 2b 
study43 and a 12-week phase 2a study42 in patients with moderate-to-severe AD, by prior CSA use 
and CSA-naive patients. 
Significance was set to P=0.05, two-sided. To account for multiplicity arising from comparison of 
each of the dupilumab+TCS dose groups with placebo+TCS, efficacy analyses were carried out in 
sequential order, following an endpoint hierarchy for each dupilumab dose regimen (see Supporting 
Information). The study was not powered for comparison of the two dupilumab dose regimens. 
Significance values were considered nominal for post hoc analyses. 
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For the primary efficacy endpoint and other binary endpoints, the Cochran-Mantel-Haenszel test 
adjusted by randomization strata (disease severity [IGA 3 or 4] and prior CsA use [yes/no], was used 
to compare each dupilumab+TCS group with placebo+TCS. Patients were specified as non-
responders at rescue medication initiation. Continuous endpoints were analysed using multiple 
imputation with analysis of covariance (ANCOVA); data after rescue medication usage was set to 
missing, and imputed by multiple imputation. For post hoc responder analyses, values after first 
rescue treatment were set to missing; patients with missing scores at Week 16 were considered non-
responders (see Supporting Information). 
Safety assessments are reported for the 16-week treatment period, and include AEs, treatment-
related AEs, SAEs, and AEs leading to discontinuation or death. 
Efficacy assessments were based on the full analysis set, which included all randomized patients, 
based on the treatment allocated as randomized (intention-to-treat). Safety analyses were based on 
the safety population, which included all randomized patients who received any study drug, based 
on the treatment received. 
Analyses used SAS£ version 9.2 (SAS Institute Inc., Cary, NC, U.S.A.) or above. 
 
RESULTS 
Patient disposition and baseline characteristics 
Between January and December 2016, 390 patients were screened and 325 randomized to 300 mg 
dupilumab qw+TCS (n=110), 300 mg dupilumab q2w+TCS (n=107), or placebo+TCS (n=108) (Fig. S1, 
Table S2; see Supporting Information).  
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Baseline characteristics were similar among treatment groups overall (Table 1), and in subgroups 
based on prior CsA use (Table S3; see Supporting Information). Median AD duration was 30 years. At 
baseline, median EASI score was 31.131.7, 75% of patients reported moderate or severe 
pain/discomfort, 59% reported sleep disruption in 37 nights over the past week, and 65% had 
previously received CsA. Most patients completed study treatment (98.2%, 100%, and 95.4%; 
qw+TCS, q2w+TCS, and placebo+TCS, respectively) by data cut-off (5 January 2017); 3 (3%) in the 
placebo+TCS group withdrew from study treatment due to lack of efficacy, and 2 (2%) each in the 
placebo+TCS and dupilumab qw+TCS groups withdrew due to AEs. 
 
Efficacy 
Primary endpoint 
The proportion of patients achieving EASI-75 at Week 16 was significantly higher in the dupilumab 
qw+TCS and q2w+TCS groups vs placebo+TCS (59.1% and 62.6% vs 29.6%, respectively; P<0.0001, 
each dose group vs placebo+TCS) (Table 2, Fig. 2a).  
Secondary endpoints 
Significantly more patients receiving dupilumab+TCS achieved EASI-50 and EASI-90 at Week 16 than 
placebo+TCS (Table 2; Fig. 2b,c). Among patients with prior exposure to CsA, significantly more 
receiving dupilumab+TCS achieved EASI-75 vs placebo+TCS (Table 2, Fig. 2d). Dupilumab+TCS 
significantly improved EASI and SCORAD scores from baseline to Week 16 vs placebo+TCS (Table 2, 
Fig. 3a,b; Table S4, Figs S2, S3), and significantly improved all other measures of clinical efficacy vs 
placebo+TCS (Table 2, Fig. S4).  
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Dupilumab+TCS significantly improved weekly average peak pruritus NRS from baseline to Week 16 
vs placebo+TCS, with significant improvement by Week 2 (Table 2, Fig. 4a, Table S4, Fig. S5). 
Significantly more patients receiving dupilumab+TCS achieved ш4-point reduction in pruritus NRS by 
Week 16 vs placebo+TCS (Table 2, Fig. 4b). 
Dupilumab+TCS significantly improved health-related quality of life (HRQOL), symptoms of AD, 
pain/discomfort, sleep, and symptoms of anxiety and depression vs placebo+TCS (Table 2, Table S4, 
Figs S68). Significantly higher proportions of patients on dupilumab+TCS achieved ш4-point 
improvement (MCID) in DLQI and POEM scores by Week 16 vs placebo+TCS (Table 2, Fig 5a,b). The 
proportion of patients who achieved HADS-A and HADS-D subscores <8 (among patients with HADS-
A or HADS-D ш8 at baseline) by Week 16 was significantly higher in the dupilumab q2w+TCS group, 
but not the qw+TCS group, vs placebo+TCS (Table 2, Fig. 5c).  
Results of sensitivity analyses were similar to the primary analyses (Table S5; Figs S25, 6b, 7b, 8b). 
Medication use 
The dupilumab+TCS groups used a lower mean weekly dose by weight of TCS vs placebo+TCS (Table 
2). Fewer patients receiving dupilumab+TCS vs placebo+TCS used rescue medication (Table 3). The 
most frequently-used rescue medication was potent TCS.  
 
Safety 
Similar proportions of patients in the dupilumab qw+TCS, q2w+TCS, and placebo+TCS groups 
reported AEs (Table 4). Few patients permanently discontinued treatment due to AEs. Two patients 
in each treatment group experienced SAEs; none were considered related to study treatment. No 
deaths occurred during the study. 
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The dupilumab+TCS groups had higher rates of conjunctivitis and injection-site reactions than the 
placebo+TCS group, while the placebo+TCS group had higher rates of non-herpetic skin infections 
and AD exacerbations (Table 4, Tables S6, S7). There were no clinically meaningful differences in 
laboratory values between treatment groups (data not shown). 
Conjunctivitis (including Medical Dictionary for Regulatory Activities Preferred Terms [MedDRA PTs] 
conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral, and atopic 
keratoconjunctivitis) was reported in 16%, 28%, and 11% of patients in the dupilumab qw+TCS, 
q2w+TCS, and placebo+TCS groups, respectively; all but one event were mild or moderate (Table S6). 
Most conjunctivitis events (89%, 62%, and 87%, respectively) were recovered/resolved or 
recovering/resolving by end of treatment (Table S6).   
Herpes viral infections were reported in 7%, 5%, and 6% of patients in the dupilumab qw+TCS, 
q2w+TCS, and placebo+TCS groups, respectively (Table S8). The more serious forms of herpes viral 
infections (e.g. eczema herpeticum, ophthalmic herpes simplex, and ophthalmic herpes zoster) 
occurred only in the placebo+TCS group. No localized herpes infections were severe and all but one 
had recovered/resolved by the end of treatment visit.  
 
DISCUSSION 
Treatment options are limited for patients with AD who previously failed to respond to CsA or 
experienced CsA-related AEs, or for whom CsA use is inadvisable because of concomitant medical 
conditions or risk of drug interactions. This study demonstrates that dupilumab+TCS significantly 
improves skin lesions, pruritus and other symptoms of AD including pain/discomfort and sleep 
disruption, symptoms of anxiety and depression, and HRQOL in this difficult-to-treat patient 
population. No new safety signals were identified in this study. Significantly more patients receiving 
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dupilumab+TCS achieved EASI-75 at Week 16 (primary efficacy endpoint) vs placebo+TCS. Among 
patients receiving dupilumab+TCS, 85% achieved a 50% reduction from baseline in EASI at Week 16  
a clinically meaningful response in this patient population with high baseline burden of disease. 
Results in the subgroup of patients with prior exposure to CsA were consistent with the overall 
population. Outcomes for the two dupilumab dose regimens were generally similar. These results 
are consistent with those of previous studies of dupilumab in patients with moderate-to-severe AD 
inadequately controlled with topical medications.4247   
This study expands upon the previous studies in two principal ways: first, unlike previous studies, the 
patients in this study were candidates for systemic treatment, and had either not responded to or 
had experienced intolerance to CsA, or were medically inadvisable to be treated with CsA; and 
second, this study evaluated dupilumab on a background of treatment with TCS and could not 
discontinue TCS, unless for safety reasons, unlike in previous studies of dupilumab with concomitant 
TCS, in which TCS could be stopped if lesions cleared.4247   
Patients with moderate-to-severe AD who need systemic therapy experience significant burden of 
disease.5660 AD symptoms can profoundly affect sleep, daily functioning, mental/emotional state, 
concomitant medication use, and HRQOL, particularly in patients with untreated or inadequately-
treated AD.5660 Improvement in patient-reported outcomes was significant in both dupilumab+TCS 
treatment groups, except for the proportion of patients who achieved HADS-A and HADS-D scores 
<8 (among patients with HADS-A or HADS-D ш8 at baseline), which was significantly greater with 
dupilumab q2w+TCS, but not qw+TCS; however, both dupilumab+TCS dose regimens showed 
significant improvement in mean change in HADS score from baseline. Improvement in pruritus was 
rapid; divergence between dupilumab+TCS and placebo+TCS was significant by Week 2. By 
significantly improving a wide range of AD symptoms (including pruritus, pain/discomfort, and 
sleep), as well as aspects of mental health and HRQOL, dupilumab+TCS improved not only skin 
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lesions but also the broader burden associated with moderate-to-severe AD in this patient 
population, consistent with previous studies.4247   
The choice of TCS background therapy as a control was consistent with European guidelines for 
patients eligible for systemic CsA,10,11,15 and reflects real-world practice. Patients receiving 
placebo+TCS used significantly more background TCS and rescue medication than the 
dupilumab+TCS groups, another indicator of better disease control with dupilumab+TCS compared 
with background TCS alone. 
Several factors may help to account for the effect of placebo+TCS treatment on efficacy. Some 
placebo+TCS effect may appear because of the natural waxing and waning clinical course of AD. In 
addition, the protocol requirement for patients with inadequate response to TCS is not the same as 
no response to TCS. As noted, patients in the placebo group applied TCS and emollients in a 
continuous manner in a controlled setting under the supervision of a principal investigator. This 
alone may be responsible for an approximate 10% improvement in the percent change in EASI score, 
as can be seen by comparing the Week 16 placebo response in LIBERTY AD CHRONOS (о48.4%)46 to 
the Week 16 response in the monotherapy LIBERTY AD SOLO 1 (о37.6%) and LIBERTY AD SOLO 2 
(о30.9%) trials.45 The effect would be expected to be greater in a trial requiring continuous use of 
TCS (unlike CHRONOS, in which patients could stop TCS if their lesions cleared). This suggests that 
even patients who were candidates for systemic therapy could still obtain some benefit of 
continuous treatment with TCS. Nonetheless, in CAFÉ the significantly greater efficacy of 
dupilumab+TCS compared with placebo+TCS demonstrates that dupilumab provides clinically 
meaningful improvement over any improvement provided by background therapy with TCS in this 
patient population. 
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Treatment groups had similar overall rates of AEs and SAEs; no new safety signals were identified. 
Dupilumab+TCS was not associated with increased overall risk of infections. Conjunctivitis and 
injection-site reactions were more frequent with dupilumab+TCS, while skin infections and AD 
exacerbations were more frequent with placebo+TCS, consistent with previous studies of dupilumab 
in AD.42,43,45,46 Decreased incidence of non-herpetic skin infections in dupilumab-treated patients in 
this study, as in previous studies, adds to the body of evidence suggesting that dupilumab may 
restore skin barrier function.  
Conjunctivitis rates in this study, especially MedRA PTs of conjunctivitis and allergic conjunctivitis, 
were higher in all treatment groups compared to previous studies.43,45,46 In addition, more patients in 
this study reported a history of allergic conjunctivitis at baseline (36.4%, 41.1%, and 54.6% 
[dupilumab qw+TCS, q2w+TCS, and placebo+TCS, respectively]) compared to previous studies (e.g. 
LIBERTY AD CHRONOS, 21.628.2%).43,45,46 This may partly be due to an increased awareness of 
conjunctivitis following publication of previous studies, as well as the regional distribution of study 
sites (most patients were from Germany and Poland), compared with previous studies, which were 
conducted not only in Europe, but also in countries from North America and Asia-Pacific. However, 
most conjunctivitis events were of mild or moderate severity and resolved while patients were still 
on treatment. No patient withdrew from study treatment because of an AE of conjunctivitis. 
Interestingly, dupilumab is not associated with increased conjunctivitis rates in studies in other 
diseases, including asthma4850 and CRsNP,51 suggesting that the increased rates of conjunctivitis in 
AD studies may reflect a unique interaction between AD- and dupilumab-related mechanisms. 
Further evaluations of conjunctivitis are ongoing to better characterize the etiology, clinical features, 
and most effective treatments. 
As a chronic disease, AD requires long-term treatment options. In the present study, dupilumab+TCS 
was evaluated for 16 weeks. Safety and efficacy of dupilumab+TCS in the present study are similar to 
those observed at 52 weeks in a subset of patients in the CHRONOS study (n/N=126/623) with 
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baseline characteristics similar to the patient population in the present study.46,61 Safety of 
dupilumab beyond 1 year is being evaluated in the open-label extension study.  
Oral CsA is a broad immunosuppressant prescribed for patients with severe AD whose disease 
warrants systemic treatment. While it may be effective in the short term in patients with severe AD, 
use of CsA is limited because of the risk of several types of side effects, and the label restricts use to 
one year.2038 In addition, cessation of CsA treatment can lead to disease rebound, which is difficult 
to manage. Concern about these issues has led to reluctance among some physicians to initiate CsA 
therapy. The data from this 16-week clinical trial show that dupilumab is highly efficacious and well 
tolerated among patients not adequately controlled with or intolerant to CsA, or when this 
treatment is medically inadvisable, giving physicians an important new treatment option. No blood 
monitoring is required for dupilumab;40,41 however, blood monitoring may be required in some 
regions based on local guidelines.  
This study had limitations. It was not designed to compare the two dupilumab dose regimens; 
however, results were similar for both regimens. In addition, the study was not designed to compare 
the CsA-experienced and CsA-naive subgroups. In both subgroups, patients had been considered for 
CsA treatment, but CsA-naive patients did not receive CsA because it was considered medically 
inadvisable (e.g. due to pre-existing hypertension, or use of statins).  
In conclusion, 16 weeks of dupilumab+TCS compared with placebo+TCS significantly improved signs 
and symptoms of AD and HRQOL, reduced use of concomitant TCS and rescue medications, and had 
an acceptable safety profile in adults with AD with history of inadequate response or intolerance to 
CsA, or for whom CsA was medically inadvisable. These data support the use of dupilumab+TCS as a 
targeted biologic therapy in this difficult-to-treat population.  
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Table 1. Baseline demographics and disease characteristics 
 Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Age, median (IQR), years 37.5 (29.049.0) 38.0 (25.0
47.0) 
38.0 (29.0
48.0) 
Race, n (%)    
White 104 (96.3) 104 (97.2) 105 (95.5) 
Asian 2 (1.9) 2 (1.9) 2 (1.8) 
Black 0 0 2 (1.8) 
Other 2 (1.9) 0 1 (0.9) 
Not reported/missing 0 1 (0.9) 0 
Male, n (%) 68 (63.0) 65 (60.7) 66 (60.0) 
Duration of AD, median (IQR), years  28.5 (19.540.0) 29.0 (19.0
43.0) 
32.0 (21.0
42.0) 
EASI score, median (IQR) 31.7 (24.240.7) 31.6 (25.2
39.2) 
31.1 (24.5
39.0) 
IGA score    
Median (IQR) 3.0 (3.04.0) 3.0 (3.04.0) 3.0 (3.04.0) 
Patients with IGA 4 (severe), n (%) 52 (48.1) 50 (46.7) 52 (47.3) 
Peak weekly averaged pruritus NRS, median 
(IQR) 
6.9 (4.98.1) 7.0 (5.48.0) 6.4 (5.27.7) 
BSA, median (IQR) 53.0 (38.369.3) 55.0 (44.0
66.0) 
55.8 (41.5
68.0) 
SCORAD score, median (IQR) 67.5 (58.576.6) 66.7 (61.1
76.2) 
66.1 (55.4
75.4) 
DLQI total score, median (IQR) 13.0 (7.019.5) 14.0 (8.022.0) 13.0 (7.021.0) 
POEM score, median (IQR) 19.0 (14.024.0) 20.0 (15.0
24.0) 
19.0 (14.0
24.0) 
HADS total score, median (IQR) 13.0 (6.018.5) 13.0 (6.019.0) 12.0 (6.019.0)
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 Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
GISS, median (IQR) 9.0 (8.011.0) 9.0 (8.011.0) 9.0 (8.010.0) 
EQ5D-pain/discomfort, n (%)    
I have no pain/discomfort 26 (24.1) 29 (27.1) 25 (22.7) 
I have moderate pain or discomfort 73 (67.6) 69 (64.5) 75 (68.2) 
I have extreme pain or discomfort 9 (8.3) 9 (8.4) 10 (9.1) 
SCORAD sleep VAS, median (IQR) 3.8 (1.47.0) 4.5 (1.67.6) 4.25 (1.37.2) 
POEM item 2: in last week nights sleep has 
been disturbed, n (%) 
   
Number of patients reporting 107 107 110 
0=no Days 12 (11.2) 17 (15.9) 24 (21.8) 
1=12 Days 35 (32.7) 24 (22.4) 19 (17.3) 
2=34 Days 19 (17.8) 21 (19.6) 15 (13.6) 
3=56 Days 18 (16.8) 12 (11.2) 22 (20.0) 
4=every Day 23 (21.5) 33 (30.8) 30 (27.3) 
Atopic/allergic conditions, n (%)  
Food allergy 41 (38.0) 51 (47.7) 54 (49.1) 
Other allergy* 71 (65.7) 76 (71.0) 76 (69.1) 
Allergic rhinitis 61 (56.5) 60 (56.1) 63 (57.3) 
Allergic conjunctivitis 59 (54.6) 44 (41.1) 40 (36.4) 
Asthma 50 (46.3) 41 (38.3) 44 (40.0) 
Chronic rhinosinusitis 10 (9.3) 7 (6.5) 8 (7.3) 
Urticaria 9 (8.3) 8 (7.5) 10 (9.1) 
Atopic keratoconjunctivitis 6 (5.6) 8 (7.5) 11 (10.0) 
Nasal polyps 6 (5.6) 0 9 (8.2) 
Eosinophilic oesophagitis 0 1 (0.9) 1 (0.9) 
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 Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Previous use of systemic 
immunosuppressants for AD, n (%) 
84 (77.8) 84 (78.5) 84 (76.4) 
Previous use of MTX, n (%) 7 (6.5) 10 (9.3) 13 (11.8) 
Previous use of AZA, n (%) 6 (5.6) 7 (6.5) 13 (11.8) 
CsA exposure, n (%)    
Yes 72 (66.7) 69 (64.5) 69 (62.7) 
Reasons for stopping the most recent 
CsA treatment 
   
CsA worked well 2 (2.8) 4 (5.8) 2 (2.9) 
Inadequate efficacy 35 (48.6) 40 (58.0) 38 (55.1) 
Because of important side effects 45 (62.5) 32 (46.4) 34 (49.3) 
To avoid important side effects 7 (9.7) 5 (7.2) 7 (10.1) 
Patient intolerance, discomfort, or 
inconvenience 
9 (12.5) 9 (13.0) 12 (17.4) 
Other 4 (5.6) 9 (13.0) 8 (11.6) 
Unknown 1 (1.4) 0 0 
No 36 (33.3) 38 (35.5) 41 (37.3) 
Reasons for no prior CsA    
Medical contraindication 27 (75.0) 27 (71.1) 24 (58.5) 
Treatment with CsA is otherwise 
inappropriate 
12 (33.3)  14 (36.8) 15 (36.6) 
Risk of important side effects is 
generally too high 
5 (13.9) 5 (13.2) 6 (14.6) 
CsA treatment is difficult to manage 0 0 1 (2.4) 
Other 1 (2.8) 3 (7.9) 1 (2.4) 
*Includes allergies to medications, animals, plants, mould, dust mites, and other. PaƟents may have 
used more than one type of immunosuppressant prior to study entry. AZA, azathioprine; BSA, body 
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surface area; CsA, ciclosporin A; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and 
Severity Index; EQ-5D, 5-dimension EuroQoL scale; HADS, Hospital Anxiety and Depression Scale; 
IGA, Investigators Global Assessment; IQR, interquartile range; MTX, methotrexate; NRS, numerical 
rating scale; q2w, every 2 weeks; qw, weekly; SCORAD, SCORing atopic dermatitis; SD, standard 
deviation; TCS, topical corticosteroids; VAS, visual analogue scale of 010 (higher numbers represent 
worse scores). 
 
Table 2. Efficacy outcomes. 
 Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Primary efficacy outcome    
Proportion of patients who achieved EASI-75 
at Week 16, n (%)  
32 (29.6) 67 (62.6)* 65 (59.1)* 
Secondary efficacy outcomes   
EASI score: LS mean percent change from 
baseline at Week 16, % (SE) 
о46.6% (2.76) о79.8% 
(2.59)* 
о78.2% 
(2.55)* 
Weekly average of peak pruritus NRS score: 
LS mean percent change from baseline at 
Week 16, % (SE) 
о25.4% (3.39) о53.9% 
(3.14)* 
о51.7% 
(3.09)* 
SCORAD score: LS mean percent change from 
baseline at Week 16 (SE) 
о29.5 (2.55) о62.4 (2.48)* о58.3 (2.45)* 
Weekly average of peak pruritus NRS score: 
proportion of patients who achieved 
improvement (reduction) ш4-point from 
baseline to Week 16, n/N1 (%)  
13/91 (14.3) 43/94 (45.7)* 38/94 (40.4)* 
Percent BSA affected: LS mean change from 
baseline at Week 16 (SE) 
о19.6 (1.80) о39.2 (1.72)* о37.5 (1.69)* 
IGA: Proportion of patients who achieved 
both IGA 0 or 1 and reduction from baseline 
of ш2 points at Week 16, n (%) 
15 (13.9) 43 (40.2)* 43 (39.1)* 
DLQI: LS mean change from baseline (SE) о4.5 (0.49) о9.5 (0.46)* о8.8 (0.45)*
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 Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
POEM: LS mean change from baseline (SE) о4.3 (0.62) о11.9 (0.60)* о11.4 (0.59)* 
Proportion of patients with prior history of 
CsA who achieved EASI-75 at Week 16, n (%) 
19 (26.4) 40 (58.0) 39 (56.5) 
Mean weekly dose (g) of TCS use (SE) 25.1 (1.48) 15.0 (1.51)* 17.5 (1.49) 
HADS: LS mean change from baseline (SE) о2.3 (0.56) о6.1 (0.54)* о5.2 (0.53) 
Other secondary efficacy outcomes    
Proportion of patients who achieved 
SCORAD-50 at Week 16, n (%) 
28 (25.9) 71 (66.4)* 61 (55.5)* 
GISS: LS mean change from baseline at Week 
16 (SE) 
о29.0 (2.75) о55.2 (2.66)* о53.3 (2.65)* 
Weekly average of peak pruritus NRS score: 
LS mean percent change from baseline at 
Week 2, % (SE) 
о10.0% (2.24) о17.2% (2.25)§  о19.7% (2.21)¶ 
Post hoc efficacy outcomesۤ    
Proportion of patients who achieved EASI-50 
at Week 16, n (%) 
47 (43.5) 91 (85.0)* 94 (85.5)* 
Proportion of patients who achieved EASI-90 
at Week 16, n (%) 
13 (12.0) 49 (45.8)* 41 (37.3)* 
Proportion of patients with ш4-point 
improvement in DLQI score at Week 16, n/N2 
(%) 
42/95 (44.2) 85/97 (87.6)* 77/99 (77.8)* 
Proportion of patients with ш4-point 
improvement in POEM score at Week 16, 
n/N3 (%) 
45/107 (42.1) 89/106 (84.0)* 84/109 (77.1)*
Proportion of patients with HADS-A and 
HADS-D <8, n/N4 (%) 
22/60 (36.7) 35/56 (62.5)¶ 26/56 (46.4)NS 
EQ-5D item 4 (pain/discomfort): proportion 
of patients reporting no problem at Week 
16, n (%)  
40 (37.0) 75 (70.1)* 69 (62.7) 
*P<0.0001 vs placebo+TCS; P<0.001 vs placebo+TCS; analysis was conducted in the population of 
patients with peak pruritus NRS score ш4 at baseline; §P<0.05 vs placebo+TCS; ¶P<0.01 vs 
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placebo+TCS; ۤall P-values for po st hoc outcomes are nominal. BSA, body surface area; CsA, 
ciclosporin A; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI-50, 
ш50% improvement from baseline in EASI score; EASI-75, ш75% improvement from baseline in EASI 
score; EASI-90, ш90% improvement from baseline in EASI score; EQ-5D, 5-dimension EuroQoL scale; 
HADS, Hospital Anxiety and Depression Scale; IGA, Investigators Global Assessment; LS, least 
squares; N1, number of patients with peak pruritus NRS score ш4 at baseline; N2, number of patients 
with DLQI score ш4 at baseline; N3, number of patients with POEM score ш4 at baseline; N4, number 
of patients with HADS anxiety (HADS-A) or depression (HADS-D) ш8 at baseline; NRS, numerical 
rating scale; NS, not significant; POEM, Patient Oriented Eczema Measure; q2w, every 2 weeks; qw, 
weekly; SCORAD, Scoring Atopic Dermatitis; SCORAD-50, ш50% improvement from baseline in 
SCORAD score; SE, standard error; TCS, topical corticosteroids; VAS, visual analogue scale of 010 
(higher numbers represent worse scores). 
 
Table 3. Use of rescue medication during the study  
 Placebo+TCS
(n=108) 
Dupilumab 
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Patients requiring ш1 rescue 
medication, n (%) 
19 (17.6) 4 (3.7) 5 (4.5) 
TCS 16 (14.8) 3 (2.8) 4 (3.6) 
Potent (group III) 11 (10.2) 3 (2.8) 2 (1.8) 
Very potent (group IV) 7 (6.5) 0 2 (1.8) 
Immunosuppressants 3 (2.8) 0 1 (0.9) 
Oral CsA 3 (2.8) 0 0 
Selective immunosuppressants 0 0 1 (0.9) 
Non-TCS topical preparations (e.g. 
TCI) 
0 1 (0.9) 0 
Systemic glucocorticoids 2 (1.9) 0 0 
CsA, ciclosporin A; q2w, every 2 weeks; qw, weekly; TCI, topical calcineurin inhibitors; TCS, topical 
corticosteroids.  
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Table 4. Adverse events  
Number (%) of patients with Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
ш1 AE  75 (69.4) 77 (72.0) 76 (69.1) 
Any drug-related AE 20 (18.5) 36 (33.6) 37 (33.6) 
Any AE causing discontinuation of study drug 
permanently 
1 (0.9) 0 2 (1.8) 
Any death 0 0 0 
Any SAE* 2 (1.9) 2 (1.9) 2 (1.8) 
Any drug-related SAE 0 0 0 
Any SAE causing discontinuation of study drug 
permanently 
0 0 1 (0.9) 
AEs (MedDRA PTs) reported by ш2% of patients 
in any treatment group  
 
Infections and infestations 44 (40.7) 49 (45.8) 47 (42.7) 
Nasopharyngitis 18 (16.7) 22 (20.6) 17 (15.5) 
Conjunctivitis 3 (2.8) 12 (11.2) 8 (7.3) 
Oral herpes 0 3 (2.8) 5 (4.5) 
Gastroenteritis 1 (0.9) 2 (1.9) 3 (2.7) 
Respiratory tract infection viral 1 (0.9) 0 4 (3.6) 
Upper respiratory tract infection 1 (0.9) 1 (0.9) 3 (2.7) 
Pharyngitis 3 (2.8) 1 (0.9) 2 (1.8) 
Respiratory tract infection 0 0 3 (2.7) 
Herpes simplex 3 (2.8) 1 (0.9) 1 (0.9) 
Skin and subcutaneous tissue disorders 21 (19.4) 22 (20.6) 21 (19.1) 
Dermatitis atopic 16 (14.8) 8 (7.5) 9 (8.2) 
Eye disorders 15 (13.9) 21 (19.6) 18 (16.4) 
Allergic conjunctivitis 7 (6.5) 16 (15.0) 10 (9.1) 
Lacrimation increased 1 (0.9) 1 (0.9) 3 (2.7) 
Eye pruritus 0 0 3 (2.7) 
General disorders and administration site 
conditions 
12 (11.1) 9 (8.4) 21 (19.1) 
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Number (%) of patients with Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Fatigue 1 (0.9) 4 (3.7) 3 (2.7) 
Injection-site reaction 0 1 (0.9) 4 (3.6) 
Injection-site erythema 1 (0.9) 1 (0.9) 3 (2.7) 
Injection-site swelling 1 (0.9) 0 3 (2.7) 
Oedema peripheral 3 (2.8) 0 2 (1.8) 
Nervous system disorders 12 (11.1) 14 (13.1) 14 (12.7) 
Headache 9 (8.3) 10 (9.3) 10 (9.1) 
Respiratory, thoracic, and mediastinal 
disorders 
14 (13.0) 14 (13.1) 14 (12.7) 
Rhinitis allergic  1 (0.9) 7 (6.5) 4 (3.6) 
Cough 1 (0.9) 4 (3.7) 3 (2.7) 
Oropharyngeal pain 2 (1.9) 3 (2.8) 1 (0.9) 
Rhinorrhoea 3 (2.8) 0 3 (2.7) 
Asthma 3 (2.8) 1 (0.9) 1 (0.9) 
Gastrointestinal disorders 16 (14.8) 9 (8.4) 9 (8.2) 
Diarrhoea 2 (1.9) 3 (2.8) 2 (1.8) 
Abdominal pain 4 (3.7) 0 4 (3.6) 
Musculoskeletal and connective tissue 
disorders 
12 (11.1) 4 (3.7) 10 (9.1) 
Myalgia 0 0 4 (3.6) 
Back pain 3 (2.8) 1 (0.9) 2 (1.8) 
Vascular disorders 1 (0.9) 4 (3.7) 3 (2.7) 
Hypertension 1 (0.9) 1 (0.9) 3 (2.7) 
Blood and lymphatic system disorders 4 (3.7) 4 (3.7) 1 (0.9) 
Lymphadenopathy 4 (3.7) 2 (1.9) 0 
Skin infections (adjudicated; excluding 
herpetic infections) 
9 (8.3) 2 (1.9) 4 (3.6) 
Treatment-emergent conjunctivitis, n (%) 12 (11.1) 30 (28.0) 18 (16.4) 
Conjunctivitis 3 (2.8) 12 (11.2) 8 (7.3) 
Conjunctivitis allergic 7 (6.5) 16 (15.0) 10 (9.1) 
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Number (%) of patients with Placebo+TCS
(n=108) 
Dupilumab  
q2w+TCS 
(n=107) 
Dupilumab
qw+TCS  
(n=110) 
Adenovirus conjunctivitis 0 1 (0.9) 0 
Conjunctivitis bacterial 2 (1.9) 1 (0.9) 0 
Conjunctivitis viral 1 (0.9) 1 (0.9) 0 
*SAEs were acute pancreatitis and hepatotoxicity (1 patient each in the dupilumab q2w+TCS group), 
ureteric calculus and AD (1 patient each in the dupilumab qw+TCS group), and hemiparesis and 
emphysema (1 paƟent each in the placebo+TCS group). MedDRA SOC; SOCs listed are those for 
which at least 1 associated PT was reported in ш2% of patients in any treatment group. MedDRA PT. 
AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; q2w, 
every 2 weeks; qw, weekly; SAE, serious AE; SOC, system organ class; TCS, topical corticosteroids.  
 
Figure legends 
Fig 1. Study design.  
aDupilumab 600 mg or matching placebo. bPatients were required to use TCS for the entire 
treatment period. CsA, ciclosporin A; q2w, every 2 weeks; qw, weekly; R, randomization (1:1:1); SC, 
subcutaneous; TCS, topical corticosteroids. 
Fig 2. (a) Proportion of patients achieving EASI-75 (primary endpoint); (b) Proportion of patients 
achieving EASI-50; (c) Proportion of patients achieving EASI-90; (d) Proportion of patients with prior 
CsA use achieving EASI-75.  
CsA, ciclosporin A; EASI, Eczema Area and Severity Index; EASI-50, ш50% improvement in EASI score; 
EASI-75, ш75% improvement in EASI score; EASI-90, ш90% improvement in EASI score; q2w, every 2 
weeks; qw, weekly; TCS, topical corticosteroids.  
Fig 3. (a) EASI: LS mean percent change from baseline, multiple imputation with censoring after 
rescue treatment use; (b) SCORAD: LS mean percent change from baseline, multiple imputation with 
censoring after rescue treatment use 
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Error bars are ±SE. EASI, Eczema Area and Severity Index; LS, least squares; MI, multiple imputation; 
q2w, every 2 weeks; qw, weekly; SCORAD, SCORing Atopic Dermatitis; SD, standard deviation; SE, 
standard error; TCS, topical corticosteroids.  
Fig 4. Weekly average of peak pruritus NRS: (a) LS mean percent change from baseline, multiple 
imputation with censoring after rescue treatment use; (b) proportion of patients achieving ш4-point 
reduction (improvement) from baseline 
Error bars are ±SE. LS, least squares; MI, multiple imputation; NRS, numerical rating scale; q2w, 
every 2 weeks; qw, weekly; SD, standard deviation; SE, standard error; TCS, topical corticosteroids.  
Fig 5. (a) DLQI: proportion of patients achieving ш4-point reduction (improvement) from baseline 
(among patients with DLQI ш4 at baseline); (b) POEM: proportion of patients achieving ш4-point 
reduction (improvement) from baseline (among patients with POEM ш4 at baseline); and (c) 
proportion of patients with HADS anxiety (HADS-A) and depression (HADS-D) <8 at Week 16 among 
patients with HADS-A or HADS-D ш8 at baseline 
DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; POEM, Patient-
Oriented Eczema Score; q2w, every 2 weeks; qw, weekly; SE, standard error; TCS, topical 
corticosteroids.  
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